As far as Myring is concerned it is all lost. Not 100% certain but believe it is exactly 12 months to the day. October 6 2020 when we received last CRL from FDA . Richards response then was “In A TIMELY MANNER” The same as 2019. Now they will respond but not inform shareholders when. Revenue for Nuvaring including Generic mis now $670m . It has dropped by 1/3. . obviously because generic suppliers are continually dropping prices to gain market share. It will be non profitable by the time we get approval ( If Ever). These two Companies are both completely incompetent regarding Generic fda approval. As stated earlier they are probably trying to approve a generic with shelf life and storage temperature range superior to Nuvaring. FDA don’t like generic manufacturing companies trying to be slick. They should just copy exactly original product. Mayne should just forget Myring and invest $$$ and time in a profitable area Richards and Fornieri ( Mithra largest shareholder are both a couple of fleas Richards should just resign with his two mates.
MYX Price at posting:
31.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)